ORDERDYNAMICS
OrderDynamics , providers of the world’s most advanced, out-of-the-box Distributed Order Management (DOM) System, today announced ground-breaking research that sheds light on omni-channel practices across the globe. Among the key findings, OrderDynamics’ Omni-1000 found that only 37 percent of retailers worldwide are offering click & collect, or buy online, pickup in-store (BOPIS).
The Omni-1000 provides a look at the actual omni-channel practices of the world’s leading retailers. Using a ‘random-walk’ methodology, OrderDynamics investigated retail websites to determine the e-commerce capabilities, policies and offerings of more than 1,000 retailers from the U.S., Canada, Australia, the UK and the Nordics (Sweden, Finland and Norway).
The research also revealed that among the retailers analyzed across the globe:
- 88.8 percent have standard e-commerce capabilities, such as the ability for shoppers to create a virtual shopping basket and purchase goods online.
- 68.4 percent provide basic inventory visibility to online consumers.
- 59.9 percent allow shoppers to buy online and return in-store (BORIS).
- 75.7 percent offer free shipping to consumers meeting a minimum purchase value threshold.
OrderDynamics also found that certain markets have significant gaps in maturity levels between them for certain omni-channel capabilities. For example, British and Nordic retailers offer click & collect services at a much higher rate than their American, Canadian and Australian counterparts.
“Omni-channel is the new backbone of retail,” said Nick McLean, CEO, OrderDynamics. “Retailers can delay the implementation of omni-channel’s essential services, but inevitably, it is that backbone which will ensure long-term viability. This is why the Omni-1000 is crucial to understanding market maturity and opportunity. It highlights the capabilities retailers need to offer to compete within the omni-channel marketplace, both in their native region and on a global scale.”
Click here to access the study and find out more about where each region ranks globally. On Thurs., Oct.12, join OrderDynamics for a live webinar reviewing the Omni-1000 findings. Click here to sign up.
About OrderDynamics
OrderDynamics is the world’s leading SaaS Order Management Systems provider. Focused on powering retail fulfillment, OrderDynamics helps clients in omni-channel retail markets. Our OMS systems give clients capabilities like order orchestration, enterprise-wide inventory visibility, returns management, customer service, and store driven fulfillment. OrderDynamics enables customer options like click and collect, and ship-from-store, creating exceptional shopping experiences. Iconic brands including Speedo, Quiksilver, J.McLaughlin, JYSK, Princess Auto, Bouclair Home, DeFacto and Browns Shoes, use OrderDynamics technology across North America, Europe, Asia and Australia. For more information, visit www.orderdynamics.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005226/en/
Contact:
OrderDynamics
Charles Dimov, 905-695-3182
Marketing Director
Charles.Dimov@OrderDynamics.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom